Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDC-01 is an investigational small interfering RNA (siRNA) therapy being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of coagulation disorders. The drug is designed to produce an anticoagulant effect through siRNA-mediated gene silencing of a specific, currently undisclosed, target within the coagulation cascade. SRNDC-01 utilizes the company's proprietary delivery platforms, which are engineered for targeted delivery to various tissues, including the liver, adipose tissue, heart, kidney, or the central nervous system (CNS). It is currently in the pre-clinical and IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDC-01.